<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:380593329;
mso-list-template-ids:1357252440;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:656231099;
mso-list-template-ids:1237598174;}
@list l1:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l1:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l2
{mso-list-id:1159997973;
mso-list-template-ids:1463075192;}
@list l2:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l2:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l2:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l2:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3
{mso-list-id:1674720433;
mso-list-template-ids:1686414984;}
@list l3:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l3:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l3:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l3:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__http://www.phrmafoundation.org/2018-awards/research-starter-grants/health-outcomes-informatics/__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKXHjILAc$" target="_blank">PhRMA Foundation: Health Outcomes Research</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The PhRMA Foundation supports the research and early-career endeavors of scientists in drug discovery and development. To that end, the foundation welcomes applications for its Pharmacoeconomics, Real
World Data and Health Outcomes Program (Health Outcomes Research). The program supports a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention, to the impact of reimbursement policies
on outcomes of care, to the development and use of patient-level real-world data and tools to perform patient-based assessments, to analyses of ways in which results of Health Outcomes Research are disseminated to providers or consumers to encourage behavior
change. Grants of up to $100,000 will be awarded to support individuals beginning independent research careers in health outcomes at the faculty level in support of:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-family:Palatino">Pharmacoeconomics — Research evaluating the behavior of individuals, organizations, and markets concerning use of pharmaceutical products, services, and programs.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-family:Palatino">Clinical Outcomes Assessment (COA) — Research dedicated to the value assigned to duration of life as modified by the impairment of physical, social, and psychological functional
states, symptoms, satisfaction, perceptions, and opportunities influenced by disease, injury, treatment, or policy.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo1"><span style="font-family:Palatino">Patient-level Real-World Data and Analytic Tools — The evolving and increasing use and evaluation of technologies, analyses, and patient-level prospective databases (e.g.,
electronic medical records, health insurance claims data, registries, patient health-networks, patient health status monitoring) to assist in better understanding disease and interventions.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 3, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: January 21.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Music and Health: Understanding And Developing Music Medicine (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-099.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKjH8SxZ4$">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-21-100.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKrqAokTQ$">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">These FOAs are intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions
to enhance health or treat specific diseases and disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">R21 Due February 16, 2021; February 16, 2022; and February 16, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 2021 due date: February 3.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">R01 Due February 5, 2021; February 5, 2022; and February 5, 2023.
<span style="color:red">Med-RA deadline to receive draft documents for February 2021 due date: January 25.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKSqw1Gbc$" target="_blank">Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the
risk for dementia or cognitive decline. The Prevention Pipeline RFP supports:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l1 level1 lfo2"><b><span style="font-family:Palatino">Studies of Cognitive Decline and Risk Reduction:</span></b><span style="font-family:Palatino"> Cognitive decline through aging and health conditions has been linked
to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain
injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under “Expectations and Evaluation”.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><b><span style="font-family:Palatino">Comparative Effectiveness Research:</span></b><span style="font-family:Palatino"> For many health conditions, physicians have a choice of clinically equivalent drugs.
Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to
generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see
Box 1 in the <a href="https://urldefense.com/v3/__https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0200-3__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK1DSTmoc$">
<b>ADDF 2016 position paper</b></a>). Methods may include randomized trials or epidemiology.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l1 level1 lfo2"><b><span style="font-family:Palatino">Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA):</span></b><span style="font-family:Palatino"> Epidemiological studies contribute
unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to supplements or medications. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate
epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis
of cohorts using a shared analysis script. <a href="https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/capa-consortium__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKqxrmK1M$">
<b>More information here.</b></a><o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-family:Palatino">Type of therapy:</span></b><span style="font-family:Palatino"> Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest
include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Drug mechanisms or modes of action:</span></b><span style="font-family:Palatino"> Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia
are considered high priority. These include, but are not limited to:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Epigenetics<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Inflammation<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Mitochondrial & metabolic function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Neuroprotection<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Proteostasis<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Synaptic activity and neurotransmitters<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Vascular function<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><span style="font-family:Palatino">Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l2 level1 lfo3"><b><span style="font-family:Palatino">Please note:</span></b><span style="font-family:Palatino"> Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors)
and cholinesterase inhibitor proposals will not be considered<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">Grants of up to $3,000,000 will be awarded for clinical trials based on stage and scope of research.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Letter of intent due February 5, 2021; May 28, 2021; October 1, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for February due date: January 25.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://klingenstein.org/esther-a-joseph-klingenstein-fund/neuroscience/applying/__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKfKo8QHE$" target="_blank">Klingenstein-Simons Fellowship Awards in Neuroscience</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Klingenstein-Simons Fellowship supports early-career investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. Several areas
within neuroscience are of particular interest:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="mso-list:l0 level1 lfo4"><span style="font-family:Palatino">Cellular and molecular neuroscience. Studies of the mechanisms of neuronal excitability and development, and of the genetic basis of behavior.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><span style="font-family:Palatino">Neural systems. Studies of the integrative function of the nervous system.<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l0 level1 lfo4"><span style="font-family:Palatino">Translational research. Studies designed to improve our understanding of the causes, prevention, diagnosis, and treatment of neurological and psychiatric disorders.<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino">$225,000 over three years, no IDC.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due February 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: February 2.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.apa.org/apf/funding/katkovsky-research-grants?tab=1__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKDpHn5dk$" target="_blank">American Psychological Foundation: Walter Katkovsky Research Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Up to $20,000. APF Walter Katkovsky Research Grants support research on the general topic of psychotherapy. Research proposals should be directed to questions and hypotheses designed to improve our understanding
based on theory or methods of how psychotherapy promotes behavioral, emotional, or cognitive changes. While the ultimate goal of the research should be to inform the psychotherapy process, its specific focus may be limited to an underlying assumption, hypothesis,
or questions; and the actual design may be “clinical” or “experimental” in terms of subjects and procedures. That is, the research design may be a simulation of some aspect of the psychotherapy process (e.g., learning or exposure trials) and subjects may or
may not be classified as “patients”.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 1, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: February 16.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21546/nsf21546.htm__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKBg9ZvLU$" target="_blank">Enabling Discovery through GEnomics (EDGE)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Through the Enabling Discovery through GEnomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative
and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The
EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to
uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype, an area relevant to
<a href="https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/big_ideas/life.jsp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK8tYeBGI$">Understanding the Rules of Life: Predicting Phenotype</a>, one of the
<a href="https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/big_ideas/index.jsp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK6-5uskQ$">10 Big Ideas</a> for NSF investment. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes.
The EDGE program will accept proposals to two submission tracks:<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">FUNCTIONAL GENOMIC TOOLS (FGT) TRACK</span></b><span style="font-family:Palatino">: Proposals submitted to this track should aim to develop and provide proof-of-concept tests of functional genomic tools
and infrastructure to enable direct tests of hypotheses about gene function in diverse species for which such tools and infrastructure are presently unavailable. Investigators may use taxonomic, question-based, and/or technology-based strategies to develop
tools and approaches that will be employed by larger communities of researchers. Projects may include instrumentation development followed by proof-of-concept testing in the context of developing functional genomic tools to enable direct tests of gene function.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">COMPLEX MULTIGENIC TRAITS (CMT) TRACK:</span></b><span style="font-family:Palatino"> Proposals submitted to this track should include hypothesis-driven research that advances understanding of the relationship
between genomes and complex multi-genic traits, toward the goal of predicting phenotypes across diverse contexts, including environmental, developmental, social, and/or genomic contexts. Successful proposals may include the development of theory and/or analytical
approaches to achieve the scientific goal. The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding complex traits requires systems-level
analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to the COMPLEX MULTIGENIC TRAITS TRACK should emphasize the contribution of genome-wide factors that impact expression of a phenotype.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">NSF-BSF Proposals:</span></b><span style="font-family:Palatino"> The EDGE program will accept proposals for the joint NSF/US-Israel Binational Science Foundation (BSF) collaborative research opportunity.
More information can be found in the Dear Colleague Letter at: <a href="https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20094__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKH5u_T50$">
https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20094</a> and subsequent replacements.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 16, 2021 and February 17, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for March due date: March 3.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21034/nsf21034.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKVO6CjGc$">NSF Dear Colleague Letter: IMAGiNE FG: Functional Genomics</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Division of Integrative Organismal Systems (IOS) has developed a thematic research focus entitled
<b>I</b>ntegrating <b>M</b>echanisms of <b>A</b>daptation with <b>G</b>enes in <b>
N</b>etworks and across <b>E</b>nvironments (IMAGiNE). A Dear Colleague Letter (DCL),
<a href="https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20044__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKoVyuO68$">NSF 20-044</a>
<b><i>IMAGiNE</i></b><i>: 2020: Organisms in a Dynamic Environment</i> – was issued that is still current and actively encouraging submission of proposals addressing how organism-environment interactions determine the emergence of complex traits. This DCL (<b><i>IMAGiNE
FG</i></b><i>: Functional Genomics</i>) complements and extends the IMAGiNE theme. Here, the focus is to encourage research on the organismal mechanisms, analytical frameworks, and biological theories that advance our understanding of the connection between
an organism’s genome and its phenotype, i.e., functional genomics. In an effort to develop strategies to move the field of functional genomics forward the National Academies of Sciences, Engineering, and Medicine (NASEM) in Washington, DC recently held a workshop
entitled “Next Steps for Functional Genomics.” <sup><a href="https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21034/nsf21034.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click*1__;Iw!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKVQjRK8A$">[1]</a></sup> The goals of the workshop were to determine the current state of research in functional genomics
and to identify the factors limiting advancements in this field. This <b>IMAGiNE FG</b>: Functional Genomics DCL acts on the proceedings of the NASEM workshop by encouraging the submission of proposals that include the dual criteria of research that (1) is
relevant to any of the programs in the <b>Integrative Organismal Systems Core Programs solicitation
<a href="https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21506__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKSGAqe38$">NSF 21-506</a></b> (, the Plant Biotic Interactions (PBI) solicitation
<a href="https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20576__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK4DQqIWc$">NSF 20-576</a>, or the Plant Genome Research Program (PGRP) solicitation
<a href="https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21507__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKnrR6FXU$">NSF 21-507</a> and (2) addresses obstacles to moving the field of functional genomics forward as identified in the NASEM workshop report.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Proposals accepted any time.
<span style="color:red">Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 / R01 Clinical Trial Optional)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-117.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKWDnYFSA$">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-116.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKqB9oNF8$">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of these Funding Opportunity Announcements (FOAs) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing
to mood disorders in people living with HIV. <o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 10, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: February 25.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Congressionally Directed Medical Research Programs<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://cdmrp.army.mil/funding/bcrp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKDVBsf_c$" target="_blank">Breast Cancer Research Program</a><br>
<b>Breakthrough Award Levels 1 and 2</b><br>
Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021. <br>
<b>Breakthrough Award Level 3</b><br>
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
<br>
<b>Breakthrough Award Level 4</b><br>
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
<br>
<b>Era of Hope Scholar Award</b><br>
Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021. Confidential letters of recommendation: June 25, 2021.
<br>
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for the above pre-application due dates: March 1.</span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-001.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKOUus_po$">Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This Funding Opportunity Announcement solicits applications on health disparities and health services-related research focusing on: 1) access to treatment, 2) making treatment more appealing, 3) costs,
and 4) dissemination and implementation. All applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 15, 2021. <span style="color:red">
Med-RA deadline to receive draft documents: March 2.</span></span></b><span style="font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-014.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKK6TkGWQ$">Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 – Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus
(T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support
epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD
complications of T1DM.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 15, 2021 and October 15, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for March due date: March 2.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-006.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKHKxy9oo$">New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not
Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and
study its dynamics in brain aging and AD/ADRD.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due June 17, 2021.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents: June 7.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-032.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKa92YdKs$">Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes
Care (R34 Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education
and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed
to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due June 22, 2021; June 22, 2022; and June 22, 2023.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 2021 due date: June 9.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-092.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKQ3c5LII$" target="_blank">NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3
Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications
for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance
them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">Due July 26, 2021; July 25, 2022; and July 25, 2023.
</span></b><b><span style="font-family:Palatino;color:red">Med-RA deadline to receive draft documents for July 2021 due date: July 13.</span></b><span style="font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:red"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:black">To search for additional funding opportunities, please visit <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69">CoM’s
unofficial funding opportunities blog</a>.</span></b><o:p></o:p></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>